Semanteon Capital Management LP Purchases Shares of 66,230 Evolent Health, Inc. (NYSE:EVH)

Semanteon Capital Management LP bought a new position in Evolent Health, Inc. (NYSE:EVH - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 66,230 shares of the technology company's stock, valued at approximately $745,000. Semanteon Capital Management LP owned about 0.06% of Evolent Health at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. R Squared Ltd purchased a new stake in shares of Evolent Health in the fourth quarter worth approximately $31,000. AlphaQuest LLC grew its holdings in Evolent Health by 21,650.0% during the fourth quarter. AlphaQuest LLC now owns 3,045 shares of the technology company's stock worth $34,000 after buying an additional 3,031 shares in the last quarter. Parkside Financial Bank & Trust grew its holdings in Evolent Health by 90.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock worth $56,000 after buying an additional 2,358 shares in the last quarter. AlphaCentric Advisors LLC bought a new position in Evolent Health during the 4th quarter valued at $61,000. Finally, Point72 Asia Singapore Pte. Ltd. lifted its stake in Evolent Health by 2,471.9% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,507 shares of the technology company's stock valued at $184,000 after acquiring an additional 6,254 shares in the last quarter.

Analysts Set New Price Targets

EVH has been the subject of several analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 target price on shares of Evolent Health in a report on Friday, February 21st. JPMorgan Chase & Co. decreased their price objective on shares of Evolent Health from $13.00 to $12.00 and set an "overweight" rating for the company in a research note on Monday, March 10th. UBS Group cut their target price on Evolent Health from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, January 16th. Royal Bank of Canada decreased their price target on Evolent Health from $20.00 to $17.00 and set an "outperform" rating for the company in a research report on Tuesday, January 14th. Finally, Oppenheimer cut their price objective on Evolent Health from $28.00 to $18.00 and set an "outperform" rating on the stock in a research report on Friday, January 24th. One investment analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Evolent Health currently has a consensus rating of "Buy" and an average target price of $17.71.

Remove Ads

Evolent Health Stock Performance

Evolent Health stock traded down $0.37 during midday trading on Tuesday, reaching $9.31. The stock had a trading volume of 1,809,963 shares, compared to its average volume of 2,123,470. The firm has a market capitalization of $1.09 billion, a PE ratio of -11.35 and a beta of 1.49. Evolent Health, Inc. has a 12 month low of $8.35 and a 12 month high of $33.63. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The firm's 50-day moving average price is $9.84 and its 200 day moving average price is $15.77.

Evolent Health (NYSE:EVH - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.35). The business had revenue of $646.54 million during the quarter, compared to the consensus estimate of $650.92 million. Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. As a group, research analysts predict that Evolent Health, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Brendan B. Springstubb bought 5,000 shares of the business's stock in a transaction on Tuesday, March 4th. The stock was acquired at an average price of $8.75 per share, for a total transaction of $43,750.00. Following the purchase, the director now directly owns 11,842 shares in the company, valued at $103,617.50. This trade represents a 73.08 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Diane Holder purchased 2,735 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were bought at an average price of $9.33 per share, for a total transaction of $25,517.55. Following the completion of the transaction, the director now owns 70,584 shares of the company's stock, valued at approximately $658,548.72. This trade represents a 4.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 74,000 shares of company stock worth $666,315. 1.60% of the stock is owned by corporate insiders.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.